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Optimising Antibiotic Usage to 
Treat Bacterial Infections
Iona K. Paterson1, Andy Hoyle1, Gabriela Ochoa1, Craig Baker-Austin2 & Nick G. H. Taylor2
The increase in antibiotic resistant bacteria poses a threat to the continued use of antibiotics to treat 
bacterial infections. The overuse and misuse of antibiotics has been identified as a significant driver 
in the emergence of resistance. Finding optimal treatment regimens is therefore critical in ensuring 
the prolonged effectiveness of these antibiotics. This study uses mathematical modelling to analyse 
the effect traditional treatment regimens have on the dynamics of a bacterial infection. Using a novel 
approach, a genetic algorithm, the study then identifies improved treatment regimens. Using a single 
antibiotic the genetic algorithm identifies regimens which minimise the amount of antibiotic used 
while maximising bacterial eradication. Although exact treatments are highly dependent on parameter 
values and initial bacterial load, a significant common trend is identified throughout the results. A 
treatment regimen consisting of a high initial dose followed by an extended tapering of doses is found 
to optimise the use of antibiotics. This consistently improves the success of eradicating infections, 
uses less antibiotic than traditional regimens and reduces the time to eradication. The use of genetic 
algorithms to optimise treatment regimens enables an extensive search of possible regimens, with 
previous regimens directing the search into regions of better performance.
The discovery of penicillin in 1928 dramatically changed human and animal health and well being. Since then, the 
discovery of additional antibiotics has further increased survival rates in areas such as surgery and during cancer 
chemotherapy. However, a lack of new antibiotics and an increase in resistance means these advances are under 
threat1. Resistance to all antibiotics in clinical use has now been observed2, with the extensive use and misuse of 
antibiotics being attributed to the spread of these resistant genes3–5. This has caused considerable debate over the 
future effectiveness in treating bacterial diseases6,7. As such, the World Health Organisation (WHO) has identified 
antibiotic resistance as one of the major health concerns of the 21st Century.
The apparent ease at which antibiotic resistance spreads is due to the ability of bacteria to acquire additional 
genes. Genes can be acquired via either mutations or horizontal gene transfer (HGT). While mutations are 
undoubtedly a source of resistance, HGT is responsible for increased propagation of resistance through bacterial 
populations8. If bacteria acquire resistant genes in an environment where they are beneficial, HGT will facilitate 
the spread of these genes within the population9. Sub-Minimum Inhibitory Concentrations (MIC) of antibiotics 
and the persistence of high levels of antibiotics within the environment have been linked to the emergence of 
resistant genes10,11. Antibiotic treatments must therefore be effective to minimise the influence of an environment 
which selects for resistance.
Effective antibiotic treatment regimens consist primarily of two variables: the dose and the duration of treat-
ment. For most antibiotics, the manufacturer identifies a traditional treatment regimen which is implemented by 
doctors and veterinary surgeons when prescribing these antibiotics. These traditional treatment regimens usually 
consist of a fixed dose administered for a specified duration. Drug efficiency studies are used to determine the 
dose and duration for these treatment regimens. However, one limitation of this approach is that it only provides 
information for the regimen being analysed and offers no indication for other potential regimens. AliAbadi and 
Lees12 highlighted the importance of rational use of antibiotics and the need to incorporate population pharma-
cokinetic (PK) and pharmacodynamic (PD) data into dosage scheduling. While traditional treatment regimens 
may be effective they may not be the optimal duration or dose at which to administer antibiotics.
As the threat of antibiotic resistance spreads the need to optimise antibiotic dosage regimens becomes essen-
tial. Mathematical modelling is increasingly being used to investigate optimal treatment regimens for antibiotic 
therapy13–17. However, these studies either omit pharmacodynamic data, by assuming that the antibiotic induced 
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death rate is constant; or only analyse a very limited number of alternative treatment regimens. With no verifica-
tion that the duration or doses chosen are optimal, these studies look for an ‘optimal’ solution from a selection of 
sub-optimal treatments. This study therefore aims to address these assumptions by considering antibiotic induced 
death as a function of the concentration of antibiotic present and by using a genetic algorithm (GA) to identify 
optimal treatment regimens. The use of a GA allows for the automatic exploration of the vast space of potential 
treatment regimens, in order to locate the most efficient ones. The effectiveness of traditional treatment regimens 
in eradicating bacterial infections will be analysed and compared to the alternative treatment regimens identified 
using the GA. This will be the first study examining the use of a genetic algorithm to optimise antibiotic treatment 
regimens.
Model
Deterministic. In keeping with previous studies9,14,18,19 a system of coupled ordinary differential equations 
are used to describe the dynamics of a population of susceptible (S) and resistant (R) bacteria. As asexual repro-
duction requires energy it is assumed that the growth rate of bacteria is limited and therefore modelled using the 
standard logistic growth equation. A cost, a, is associated with carrying the genes which infer resistance to anti-
biotics20 and results in a reduced growth rate for the resistant strain. Genes can pass from resistant to previously 
susceptible bacteria through HGT, β, resulting in the loss of susceptible bacteria and the addition of resistant 
bacteria. There are 3 main mechanisms of HGT: transformation, transduction and conjugation. This study does 
not distinguish between the differing modes of HGT. Both susceptible and resistant bacteria die at a natural death 
rate, θ, and through exposure to antibiotics, Ai(C).
Antibiotics are added to the system in daily doses. When = ˆt tn the concentration of antibiotic 
C(t) = C(t) + Dn, where =ˆ ···t (1, 2, 3, , 10) and D is a vector of doses D = (D1, D2, … , D10). Traditional treatment 
regimens assume that D1 = D2 = … = D10, however this study relaxes this constraint. Treatment regimens within 
this study are limited to a maximum of 10 doses but this could be increased indefinitely. The full model can there-
fore be written as equations 1, 2 and 3. A full list of parameters and values can be found in Table 5 (see methods 
section).
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Degredation
Stochastic. Deterministic modelling contains no randomness and as a result produces the same outcome 
each time it is run. Provided the population densities are not too small, deterministic models produce good 
approximations of the system dynamics. However hosts treated with the same treatment regimen will not all 
respond in exactly the same way. The small population size of resistant bacteria mean that stochastic events may 
lead to the emergence or extinction of a resistant strain. A stochastic framework was therefore produced for 
equations 1, 2 and 3. Simulations are run for 30 days to allow for infection to return if treatment regimens are 
unsuccessful. Each treatment regimen was run 5000 times with the infection either being eradicated or still pres-
ent at the end of the 30 days. The percentage of runs which resulted in eradication of the infection produced the 
success rate for each regimen. Due to the ability to simulate the model thousands of times the variability within 
the results is small. However, the 95% confidence interval for each treatment was calculated in MATLAB using 
the Clopper-Pearson exact confidence interval21. This method was chosen due the occurrence of success rates 
close to 100%. The median time to eradication for all successfully eradicated infections was also calculated. (This 
data was not normally distributed and therefore the median was used instead of the mean).
Results
Numerical simulations were run to analyse the effect different treatment regimens have on the population size of 
bacteria within an infection. The success rate and time to eradication of the infection were analysed. Treatment 
regimens are obtained from traditional regimens and from solutions derived using a GA. The results presented 
were performed with an initial resistant population of 10% of the total bacterial population. When analysed 
with an initial resistant population of 1% of the total bacterial population the results follow a similar pattern (see 
Supplementary Table S1).
Traditional Treatment Regimens. Using traditional treatment strategies of a constant dose administered 
for 10 days the minimum daily dose required to successfully treat the infection is 23 μg/ml (Fig. 1). Under this 
regimen the infection is successfully eradicated in 99.8% (95% CI: 99.6, 99.9) of cases (n = 5000 for all simula-
tions). Administering 23 μg/ml of antibiotics per day increases the concentration of antibiotic within the system 
over the 10 days, reaching a peak of 60 μg/ml on day 10 (Fig. 1b).
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From Fig. 1b it is noted that it takes 3 days before the concentration of antibiotic is maintained above the MIC 
of the resistant strain. During these first 3 days the population of resistant bacteria increases (Fig. 1a). Once above 
the MIC of the resistant strain the population begins to decrease. If the infection is not eradicated under the tra-
ditional treatment regimen then a resistant infection will emerge.
Until now the study assumed that traditional treatment regimens are administered over 10 days. This assump-
tion was relaxed and the success rate of eradicating the infection over a shorter duration examined (Table 1). 
Shorter treatment duration results in a decrease in the success rate of eradicating the infection. Treatment dura-
tion fewer than 8 days experiences a substantial decrease in success rate, to below 90%.
The time taken to eradicate the bacterial population was also measured. This time was only recorded in the 
cases where the treatment was successful and the bacterial population completely eradicated. There is a small 
decrease in the time to eradication as the treatment duration decreases from 10 days to 7 days. However, this 
is due to the shorter regimen leading to a lower success rate. The 7 day traditional treatment is unable to erad-
icate infections which persist beyond 8 days due to the antibiotic continuously degrading beyond the last day 
of treatment. Due to these persistent infections not being eradicated the median time to eradication lowers in 
comparison to the longer traditional treatment regimens. As the treatment length increases above 7 days the 
success rate also increases. The median increase in success rate from 8 days to 10 days is 3.4% but requires 18.7% 
more antibiotic to achieve this. To maintain a success rate of over 90%, under a traditional treatment regimen, this 
infection can be treated by administering a minimum of 184 μg/ml of antibiotic over 8 days. This regimen results 
in a success rate of 96.4% and is used as the baseline to look for improved treatments.
Tailored Treatment Regimens. A genetic algorithm (GA) was used to identify effective dosage vectors, 
D = (D1, D2, … , D10), which would maximise the success rate of eradicating the infection by minimising the 
fitness (objective) function (Eq. 4).
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Minimising the total amount of antibiotic used, ∑ iDi, exposes the environment to less antibiotic reducing the 
likelihood of resistance developing. However, using less antibiotic increases the total bacterial burden on the host 
over the length of the infection, ∫ N t dt( )0
30 , where N = S + R. The increased bacterial load not only compromises 
the health of the host but also offers more opportunity for mutations to arise increasing the risk of further resist-
ance developing. A trade-off exists between the total amount of antibiotic used and the total bacterial load over 
the course of the infection. Weights w1 and w2 allow for more emphasis to be placed on minimising one term over 
the other. To ensure a trade-off exists, .⩾w 0 0011  and .⩾w 0 0012  (However, this study later considers the case 
where w1 = 0, hence the objective is solely to maximise treatment success.) Due to the difference in the magnitude 
of the values of each term, correcting factors α1 and α2 were used to transform the terms between 0 and 1.
Genetic Algorithm with the Deterministic Model. Due to the toxic nature of antibiotics the total anti-
biotic concentration within the system at any point in time was constrained to a maximum of 60 μg/ml within the 
Figure 1. Dynamics of the model over 30 days with antibiotic therapy administered at a daily dose of 
23 μg/ml for the first 10 days. (a) Stochastic simulations of the population dynamics of both susceptible 
(blue) and resistant (green) bacteria with the deterministic dynamics (bold) overlaid. 5000 simulations were 
run producing a success rate of eradicating the infection of 99.8% (95% CI: 99.6, 99.9). (b) Simulation of the 
concentration profile of antibiotic present within the system over the 30 day duration. The MIC lines indicate 
the concentration of antibiotic required to inhibit the growth of the respective bacterial strain, 16 μg/ml for 
susceptible bacteria and 32 μg/ml for resistant bacteria. A maximum antibiotic concentration of 60 μg/ml is 
observed on Day 10.
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GA. This is in keeping with the maximum concentration from the traditional treatment regimen (although this 
could be relaxed if needed). The GA was run for varying maximum daily dosages of 60, 50 and 40 μg/ml per day. 
The successful dosage vectors were then run through a stochastic model to generate a success rate of eradicating 
the infection.
The dosage vectors from the GA begin with an increased dose which tapers off as the treatment progresses 
(Table 2). Results from the GA suggests that the duration of therapy could be as little as 4 days (Table 2, regimens 
D1 and D3). However, these treatment regimens have a lower success rate, 91.2% (95% CI: 91.0, 92.5) and 92.3% 
(95% CI: 91.5, 93.0), than the traditional regimen, 96.4% (95% CI: 95.8, 96.9). For all three maximum daily doses, 
the longer duration regimens (Table 2, regimens D2, D5 and D8) are more efficient at treating the infection than 
the shorter durations with success rates of 94.3% (95% CI: 93.6, 94.9), 94.4% (95% CI: 93.7, 95.0) and 95% (95% 
CI: 94.4, 95.6) respectively. The lack of noise within the deterministic model allows the GA to be very effective in 
minimising the total antibiotic used. When the shorter dosage vectors from the GA using the deterministic model 
are analysed using the stochastic model there is too little antibiotic administered over too short a duration leading 
to the emergence of resistant bacteria.
The total concentration of antibiotic in the traditional regimen (Fig. 1b) increases slowly over the 8 days. The 
regimens from the GA start with an initial high dose followed by tapering smaller doses which maintain the total 
concentration of antibiotic above the MIC of the resistant bacteria for the majority of the duration of treatment 
(Fig. 2). All three regimens D2, D5 and D8 use less antibiotic in total over a shorter duration than the traditional 
regimen. Regimen D2 uses 30% less antibiotic over 5 days instead of 8. Regimen D5 produces a dosage vector 
which uses 23% less antibiotic than the traditional regimen and delivers it over 6 days instead of 8. The dosage 
vector from D8 uses 15% less antibiotic and is shorter by 1 day in duration.
All the regimens identified by the GA see a reduction in the time to eradication for the infection. The median 
time to eradication for the 8 day traditional treatment was 7.13 days (95% CI: 7.04, 7.20). By distributing the 
antibiotic in a high initial dose with tapering smaller doses the median time to eradication for all the the regimens 
identified by the GA is between 4 and 5.5 days.
Genetic Algorithm with the Stochastic Model. The GA was run using a stochastic model to maximise 
the probability of eradication and explore the effectiveness of a longer treatment duration. For the GA using the 
stochastic model the second term, minimising the bacterial load, in F (Eq. 4) was replaced with a term minimis-
ing the number of unsuccessful runs out of the 5000. Due to the increased run time, only a few results could be 
given (Table 3).
The dosage vectors from the stochastic model are noisy due to the randomness in the model. Despite this, the 
dosage vectors begin to converge to a similar pattern identified using the GA with the deterministic model. A 
large initial dose followed by an extended period of tapering lower doses is observed. The median time to eradica-
tion for the stochastic results are comparable to the deterministic results. However, by using more antibiotic over 
the longer treatment duration the stochastic regimens have a greater success rate. Despite the increase in total 
antibiotic these dosage vectors use between 11 and 19% less antibiotic than the traditional regimen with a similar 
or increased success rate. Dosage regimen S2 has the greatest success rate, 98.4% (95% CI: 97.7, 98.5), an increase 
on the traditional 8 day treatment, 96.4% (95% CI: 95.8, 96.9). The GA was able to identify alternative treatment 
regimens using less antibiotic with a success rate of eradication equal to or better than the traditional treatment. 
The alternative regimens also successfully treat the infection over a shorter duration than the traditional regimen, 
around 4 to 5 days, vs. 7 to 7.5 days respectively.
If the priority is not to reduce the total antibiotic used, the GA can be implemented to maximise the effec-
tiveness of current regimens. In this case, how can the 184 μg/ml of antibiotics be distributed to maximise the 
probability of eradication? (i.e. set w1 = 0 in Eq. 4) The GA identifies a high initial dose followed by a tapering of 
doses (Table 3, regimen S4) as the optimal distribution of the antibiotics. This regimen resulted in a success rate 
of 99.7% (95% CI: 99.5, 99.8) compared to 96.4% (95% CI: 95.8, 96.9) obtained from the traditional treatment 
(Table 1). This regimen also eradicates the infection quicker than the traditional regimen with a median time 
to eradication of 3.94 days (95% CI: 3.89, 3.99) compared to 7.13 days (95% CI: 7.04, 7.19) for the traditional 
regimen.
Sensitivity Analysis. Due to the difficulty in obtaining exact parameter values for an infection, the effect 
changes in parameter values have on the success rate of different treatment regimens was analysed. Parameter 
Dosage Vector Total Antibiotic
Success Rate (%) 
[95% CI, n = 5000]
Time to Eradication 
(days) [95% CI]
T1 (23, 23, 23, 23, 23, 23, 23, 23, 23, 23) 230 μg/ml 99.8 [99.6, 99.9] 7.31 [7.23, 7.39]
T2 (23, 23, 23, 23, 23, 23, 23, 23, 23, 0 ) 207 μg/ml 99.0 [98.7, 99.3] 7.29 [7.19, 7.35]
T3 (23, 23, 23, 23, 23, 23, 23, 23, 0, 0 ) 184 μg/ml 96.4 [95.8, 96.9] 7.13 [7.04, 7.19]
T4 (23, 23, 23, 23, 23, 23, 23, 0, 0, 0 ) 161 μg/ml 87.4 [86.4, 88.3] 7.12 [7.04, 7.20]
Table 1.  Comparison of success rate and time to eradication for traditional treatment dosage vectors 
of varying duration. For time to eradication of regimens T1, T2, T3 and T4; n = 4990, 4950, 4820 and 4370 
respectively.
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values relating to the virulence of the bacteria; replication rate (r), transmission rate (β) and cost of resistance 
(a) were examined. Further sensitivity analysis was performed for parameters concerning the effectiveness of 
the antibioitcs: degradation rate (g), MIC of susceptible (micS) and resistant bacteria (micR) and the shape of the 
antibiotic death function (k). Changes in parameters r, a, g and micR show the greatest change and can be found in 
Figure 3. Other results can be found in Supplementary Figure S1. Analysis was performed on the traditional 8 day 
treatment regimen (Table 1, regimen T3) and GA generated treatment regimens (Table 3, regimens S2 and S4).
As r, g and micR decrease, the success rate for all three treatment regimens converge towards 100%. At these 
lower parameter values the tapered regimens have no benefit over the traditional regimen. However, as r, g and 
micR increase the success rates for all 3 treatments decrease. As the parameter values continue to increase the 
benefit of the new tapered regimens increase significantly over the traditional regimen. The cost of resistance 
follows a similar pattern. As a increases the three treatment regimens are equally as effective with all success rates 
converging to 100%. However, when a is decreased the success rates for all three treatments also decrease. Despite 
the decrease in success rates the tapered regimens obtained from the GA perform better than the traditional 
regimen. When there is no cost of resistance the success rate of the traditional regimen dropped to below 50% 
at 45.7% (95% CI: 44.3, 47.1) whereas the tapered regimens remain significantly higher at 79.3% (95% CI: 78.2, 
80.4) and 92.4%(95% CI: 91.6, 93.1). Across all the parameter values analysed regimen S4 consistently maintains 
a success rate above 90%. Whereas when the same amount of antibiotic is distributed in a traditional manner the 
Dosage Vector
Total 
Antibiotic
Success Rate (%) 
[95% CI, n = 5000]
Time to Eradication 
(days) [95% CI]
D1 (60, 21, 22, 15, 0, 0, 0, 0, 0, 0) 118 μg/ml 91.2 [91.0, 92.5] 3.93 [3.88, 3.99]
D2 (60, 22, 18, 17, 11, 0, 0, 0, 0, 0) 128 μg/ml 94.3 [93.6, 94.9] 3.98 [3.94, 4.04]
D3 (50, 29, 22, 21, 0, 0, 0, 0, 0, 0) 122 μg/ml 92.3 [91.5, 93.0] 4.12 [4.06, 4.17]
D4 (50, 28, 20, 20, 10, 0, 0, 0, 0, 0) 128 μg/ml 93.2 [92.5, 93.9] 4.17 [4.11, 4.23]
D5 (50, 19, 21, 23, 18, 10, 0, 0, 0, 0) 141 μg/ml 94.4 [93.7, 95.0] 4.56 [4.50, 4.64]
D6 (40, 35, 23, 21, 13, 0, 0, 0, 0, 0) 132 μg/ml 92.5 [91.7, 93.2] 4.46 [4.41, 4.51]
D7 (40, 26, 26, 23, 17, 11, 0, 0, 0, 0) 143 μg/ml 94.0 [93.2, 94.5] 4.77 [4.71, 4.86]
D8 (40, 21, 27, 18, 26, 13, 11, 0, 0, 0) 156 μg/ml 95.0 [94.4, 95.6] 5.33 [5.26, 5.41]
Table 2.  Comparison of dosage vectors produced by the GA with deterministic modelling. Regimens D1, 
D3 and D6 represent the best dosage vectors with maximum daily doses of 60, 50 and 40 μg/ml respectively. All 
other runs represent the best dosage vector of increased treatment duration. For Regimens D1–D8; n = 4560, 
4715, 4615, 4660, 4720, 4625, 4700 and 4750 respectively.
Figure 2. Concentration profiles for regimens D2, D5 and D8 from the dosage vectors identified by the 
GA with deterministic modelling. (a) Treatment regimen D2 maintains an antibiotic concentration above the 
MIC of the resistant strain throughout the 6 day treatment. The maximum total concentration of antibiotic is 
60 μg/ml. (b) D5 also maintains a concentration above the MIC for the resistant bacteria throughout the 6 day 
treatment reaching a maximum total concentration of 54 μg/ml on day 4. (c) The concentration of antibiotic 
throughout D8 increases above the MIC of the resistant bacteria initially but drops back below for the first 
two days. The concentration is then maintained above the resistant MIC for the remainder of the treatment, 
reaching a maximum concentration of 58 μg/ml on day 5.
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success rate can drop to below 50%. Despite regimen S2 using less antibiotic it also consistently performs better 
than the traditional regimen.
While the previous tapered regimens perform well when the parameter values are altered, they are not nec-
essarily the optimal dosage vectors for these new parameter sets. To examine whether the tapered effect was a 
consequence of the parameter values chosen the GA was used to generate optimal dosage vectors for the varied 
parameter values found in Fig. 3. In every run of the GA, the optimal solution was an initial high dose followed 
by tapering doses. Although the optimal solutions do not change qualitatively, i.e. high dose with tapering, the 
exact doses do vary substantially. An example is shown in Table 4 where the growth rate was varied by 10%. Here 
the same pattern holds qualitatively but there was variation in the exact doses. Tapered regimens may be optimal, 
however the exact doses need to be personalised across infections.
Discussion
Current antibiotic treatment regimens consist of a fixed daily dose administered for a set duration. While these 
traditional regimens may be easier to administer due to the constant dose, there is little evidence that this is the 
optimal way of administering antibiotics. Despite the continued increase in antibiotic resistance these traditional 
treatment regimens remain largely unchanged. More research must be dedicated to ensuring we are using anti-
biotics in an optimal way.
This study considered a traditional treatment regimen of 23 μg/ml of antibiotic per day for 10 days. While this 
regimen successfully eradicated the infection in 99.8% of cases, the daily dose of antibiotic falls between the MIC 
of the susceptible and resistant bacteria initially facilitating the emergence of resistance. This is due to the time 
it takes for the total concentration of antibiotic to increase above the MIC of the resistant strain. While between 
the two MIC points the susceptible bacteria are eradicated allowing the resistant population to increase with little 
competition. Provided treatment is continued, the concentration of antibiotic will eventually increase above the 
MIC of the resistant strain.
The GA, using the deterministic and stochastic models, identified that optimal dosage vectors contain an ini-
tial high dose followed by tapering lower doses. Initially increasing the concentration of antibiotic above the MIC 
of the resistant bacteria eradicates the selective advantage observed in the traditional treatment regimen. Smaller 
doses of antibiotic are then administered to maintain the concentration above the MIC of the resistant strain. 
In the example shown the tapered regimens reduce the amount of antibiotic required to successfully treat the 
infection by as much as 23%. In some regimens produced by the GA, the maximum concentration of antibiotic 
within the system was lower than that observed with the traditional treatment regimen (Fig. 2) despite prescrib-
ing higher doses. With increased levels of antibiotic selecting for increased resistance, the ability to successfully 
treat an infection while maintaining a lower total antibiotic concentration over a shorter duration minimises the 
risk of higher resistance being selected for.
If traditional treatment regimens are adapted to deliver doses above the MIC of the resistant strain then the 
initial facilitation of resistant bacteria will disappear. However, the total antibiotic concentration within the sys-
tem will considerably increase. In this scenario increasing the daily dose to above that of the MIC of the resistant 
strain would increase the total antibiotic concentration to beyond the level determined as toxic, 60 μg/ml, after 
3 days.
The set duration of treatment is often subjective with increased length being used as a precaution. Studies 
have looked to find the optimal length of therapy22–24 but potential treatment durations are based on empirical 
evidence. This study used a mathematical model as a way to determine the time to eradication of the infection 
and therefore the minimum duration of treatment required. The 10 day traditional treatment has a median time 
to eradication of 7.31 days. Additional antibiotic treatment beyond 8 days resulted in a small increase in success 
rate despite a larger increase in total antibiotic required. Whereas treatment length fewer than 8 days (shorter 
than the time to eradication) resulted in a much lower success rate. A traditional treatment regimen of 23 μg/ml 
of antibiotic per day for 8 days was therefore taken as a baseline treatment.
The GA can be used to redistribute the antibiotic within the traditional regimen to produce a more efficient 
treatment regimen. The 8 day traditional treatment used 184 μg/ml of antibiotics and achieved a success rate of 
96.9% with a time to eradication of 7.13 days. The alternative treatment regimen identified by the GA applied the 
184 μg/ml of antibiotic in a high dose tapered regimen to achieve a success rate of 99.7% with a time to eradica-
tion of 3.94 days. This success rate is comparable with the success rate for the 10 day traditional treatment but the 
GA generated regimen uses 20% less antibiotic over fewer days to achieve it. By redistributing the antibiotic in a 
Dosage Vector
Total 
Antibiotic
Success Rate (%) 
[95% CI, n = 5000]
Time to Eradication 
(days) [95% CI]
S1 (60, 19, 17, 16, 19, 18, 0, 0, 0, 0) 149 μg/ml 96.9 [96.2, 97.2] 4.14 [4.09, 4.20]
S2 (50, 25, 24, 20, 20, 12, 0, 0, 0, 0) 151 μg/ml 98.4 [97.7, 98.5] 4.23 [4.18, 4.31]
S3 (40, 27, 21, 22, 23, 12, 18, 0, 0, 0) 163 μg/ml 97.1 [96.6, 97.5] 5.03 [4.96, 5.11]
S4 (60, 22, 22, 22, 18, 15, 14, 11, 0, 0) 184 μg/ml 99.7 [99.5, 99.8] 3.94 [3.89, 3.99]
Table 3.  Comparison of dosage vectors produced by the GA with stochastic modelling for maximum daily 
doses of 60, 50 and 40 μg/ml and the case where all 184 μg/ml of antibiotic is used. n = 4845, 4920, 4855 and 
4985 for time to eradication of S1, S2, S3 and S4 respectively.
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high dose, tapered pattern the time to eradication of the infection reduces considerably, allowing shorter treat-
ment regimens to be just as effective.
Studies have shown that shorter treatment regimens can be effective in treating bacterial infections25,26 with 
initial loading dose treatments being beneficial in treating patients in critical care medicine27. Tapered regimens 
have been found to be effective when treating Clostridium difficile28,29. However, the use of tapered regimens 
resulted in sub-optimal performance in previous studies using optimal control strategies30,31. From the sensitivity 
analysis it is shown that as the parameters are altered it is possible for the success rate of a tapered regimen to drop 
significantly. In the case of reducing the cost of resistance the success rate for the tapered regimen dropped to 
below 80%. However, when the GA is used to identify an optimal solution for the new parameter set it produces 
the same tapered pattern but with different dose values. Generic tapering regimens will not always be the most 
efficient regimen. The sensitivity in the doses required for a successful tapering regimen indicates that personali-
sation of individual treatments is required. Such personalisation can be achieved with the use of a GA. Despite the 
need for personalisation the tapered regimens consistently performed better than the traditional regimen when 
the infection was more virulent or the antibiotic was less effective.
Using a GA to search for an effective treatment regimen allowed for a constrained search of all possible dos-
age vectors. The lack of noise within the deterministic model allows the GA to converge to a specific minimum 
antibiotic concentration. However, when this is analysed using the stochastic model, random events mean these 
treatments are not as efficient. The stochastic model therefore identifies slightly longer treatments with more 
antibiotic than the deterministic model, increasing the success rate. The increased computation time of the GA 
using the stochastic model makes it inefficient. The GA using the deterministic model is much less computation-
ally expensive and produces the same loading dose but with a shorter tapered duration than the results using the 
stochastic model. The results from the deterministic model still have value and provide a suitable starting point 
from which to base potential future treatment regimens.
The use of the GA suggests that, in order to optimise antibiotic treatment regimens, the idea of constant doses 
needs to be addressed. Research indicates that the use of combination or sequential treatments are more effective 
in preventing resistance13,15,32. However, these studies use sub-optimal traditional treatments as comparisons 
and therefore single antibiotic treatments should not be ruled out. Genetic algorithms provide an efficient way of 
Figure 3. Success rates for regimens S2 (pink), T3 (red) and S4 (blue) at varying values for parameters (a) a, 
(b) r, (c) g and (d) micR. Black dashed line shows original parameter values. As parameter values are altered 
to benefit the infection success rates for all three treatment regimens decrease. With the tapered regimens 
performing better than the traditional regimen. If parameter values are altered to disadvantage the infection the 
three regimens converge to a similar success rate.
Parameter Value Dosage Vector Total Antibiotic
r
2.5 (60, 21, 16, 16, 17, 13, 0, 0, 0, 0) 143 μg/ml
2.7 (50, 19, 21, 23, 18, 10, 0, 0, 0, 0) 141 μg/ml
3 (44, 32, 23, 14, 18, 0, 0, 0, 0, 0) 131 μg/ml
Table 4.  Optimal dosage vectors achieved when growth rate is altered by ±10%.
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identifying and investigating the potential use of alternative single, and multiple, antibiotic treatment regimens to 
prolong the effectiveness of current antibiotics.
Methods
Antibiotic Death Rate. Experimental data33,34 suggests that as the concentration of antibiotic increases the 
death rate increases until it reaches a saturation point. In addition, the concentration of antibiotic naturally decays 
within a host. The concentration of antibiotic is therefore modelled according to first order kinetics with an elim-
ination constant g. The half-life of the antibiotic is therefore given by =t
g
1
2
ln(2) .
To model the relationship between antibiotic concentration and antibiotic induced death rate the extension of 
the Emax model of antibiotic treatment by Regoes et al.30 was used (Eq. 5).
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Parameter Values. The parameter values (Table 5) were chosen such that in the absence of antibiotics the 
resistant strain would not out-compete the susceptible strain. Analytical analysis of the model was performed to 
identify the conditions which meet this criteria (see Supplementary Equations). This ensures that if resistance 
invades it is due to the treatment regimen and not a result of the dynamics of the system.
Stochastic Modelling. This study uses the well-established Gillespie algorithm35 to obtain stochastic sim-
ulations for the different treatment regimens. By calculating the probability of the individual events occurring, 
based on rates and parameter values from the deterministic model, the Gillespie algorithm randomly chooses the 
next event to happen and the time at which it will happen. The population of each bacteria is adjusted accordingly 
and the process is repeated. As the events are chosen randomly each simulation will be slightly different. The suc-
cess rate for each treatment regimen was obtained by calculating the total number of simulations which resulted 
in the eradication of both susceptible and resistant bacteria.
Genetic Algorithms. Genetic algorithms were proposed by John Holland in the early 1970’s36. They belong 
to the larger class of evolutionary algorithms, which generate solutions to optimisation problems using techniques 
inspired by natural evolution, such as inheritance, mutation, selection and crossover37. GAs have previously been 
used to generate treatment schedules for chemotherapy treatment38,39. Despite being a randomised search GAs 
are by no means random, instead they use historical information to direct the search into the region of better 
performance within the search space. The GA uses the deterministic model to run simulations using the gener-
ated dosage vectors. Values from these simulations are then used to compute the fitness function for that dosage 
vector. The fitness function of each generated dosage vector are compared with the search space moving towards 
the vector with the smallest fitness function. (The GA was implemented using MATLAB with a population size 
of 100, for 1000 generations and repeated 50 times with values of 0.01 and 0.99 for Eq. 4, w1 and w2, respectively). 
Varying the weights had no significant effect on the results (see Supplementary Table S2). Solutions were then run 
through the Gillespie algorithm to produce a success rate of eradication for each vector.
An alternative approach is to use the stochastic model as part of the fitness function evaluation within the GA. 
However, the computational time increases substantially (in the order of 103) compared to using the deterministic 
model.
Parameter Description Value
r Replication Rate 2.7726
K Carrying Capacity 1000
β Rate of Transmission of Resistant Plasmid 0.00001
θ Natural Death Rate 0.2
a Cost of Resistance 0.2
g Degradation rate of antibiotic 0.48
minS Min net growth at high AB concentrations − 2.1
maxS Max net growth in absence of AB r − θ
micS Min inhibitory concentration (MIC) 16
kS Hill coefficient 4
minR Min net growth at high AB concentrations − 2.1
maxR Max net growth in absence of AB r(1 − a) − θ
micR Min inhibitory concentration (MIC) 32
kR Hill coefficient 4
Table 5.  List of parameters and values.
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